GENETHON
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1990-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.genethon.fr
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genethon
- Target Recruit Count
- 3
- Registration Number
- NCT06518005
- Locations
- 🇫🇷
Hopital Antoine BECLERE, Clamart, France
Natural History of Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Genethon
- Target Recruit Count
- 100
- Registration Number
- NCT03882827
- Locations
- 🇫🇷
CHU Lille, Lille, France
🇫🇷Brest University Hospital Centre, Brest, France
🇫🇷University Hospital of Bordeaux, Bordeaux, France
Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I
- Conditions
- LGMD2I
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Genethon
- Target Recruit Count
- 52
- Registration Number
- NCT03842878
- Locations
- 🇩🇰
Pr John Vissing, Copenhagen, Denmark
🇫🇷Dr Tanya Stojkovic, Paris, France
🇬🇧Pr Volker Straub, Newcastle, United Kingdom
Gene Therapy for Severe Crigler Najjar Syndrome
- Conditions
- Crigler-Najjar Syndrome
- Interventions
- Genetic: GNT0003
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Genethon
- Target Recruit Count
- 17
- Registration Number
- NCT03466463
- Locations
- 🇳🇱
AMC, Amsterdam, Netherlands
🇮🇹ASST Papa Giovanni XXIII, Bergame, Italy
🇮🇹Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
Gene Therapy for X-linked Chronic Granulomatous Disease
- Conditions
- X-Linked Chronic Granulomatous Disease
- Interventions
- Genetic: X vivo gene therapy
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Genethon
- Target Recruit Count
- 3
- Registration Number
- NCT02757911
- Locations
- 🇫🇷
Hôpital Necker Enfants Malades, Paris, France
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
- Conditions
- Wiskott-Aldrich Syndrome
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Genethon
- Target Recruit Count
- 10
- Registration Number
- NCT02333760
- Locations
- 🇬🇧
UCL Institute of Child Health, London, United Kingdom
🇫🇷Hopital Necker - Enfants Malades, Paris, France
Immunity Against AAV in Crigler Najjar Patient
- Conditions
- Crigler Najjar Syndrome
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Genethon
- Target Recruit Count
- 49
- Registration Number
- NCT02302690
- Locations
- 🇫🇷
Hopital Antoine Béclère, Clamart, France
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
- Conditions
- X-Linked Chronic Granulomatous Disease
- Interventions
- Genetic: X vivo gene therapy
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Genethon
- Target Recruit Count
- 3
- Registration Number
- NCT01855685
- Locations
- 🇬🇧
University College London Hospital (UCLH), London, United Kingdom
🇬🇧Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Genethon
- Target Recruit Count
- 45
- Registration Number
- NCT01385917
- Locations
- 🇬🇧
Great ormond Street Hospital & University College London Hospital, London, United Kingdom
🇫🇷Myology Institute, Paris, France
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Genethon
- Target Recruit Count
- 220
- Registration Number
- NCT01380964
- Locations
- 🇫🇷
Institute of Myology, Paris, France